Chimeric Therapeutics announces breakthrough AML response with CHM CORE-NK in Phase 1B trial
Chimeric Therapeutics has reported a significant milestone in its ongoing clinical trials, wherein a patient diagnosed with Acute Myelogenous Leukemia (AML) has exhibited a complete ... Read More
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More
Gamma Biosciences to sell Mirus Bio to Merck KGaA for $600m in key biotech deal
Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading global science and technology company, has agreed to acquire Mirus Bio from Gamma Biosciences for $600 million in ... Read More
Takeda Pharmaceutical set to acquire TiGenix for €520m, enhancing gastroenterology and specialty care offerings
Japanese pharmaceutical giant Takeda Pharmaceutical has announced a proposal to acquire TiGenix, a Belgium-based cell therapy company, for €520 million. This acquisition is aimed at ... Read More